Mangalam Drugs & Organics Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 620.88 million compared to INR 938.36 million a year ago. Revenue was INR 634.61 million compared to INR 1,018.78 million a year ago. Net income was INR 4.26 million compared to INR 40.22 million a year ago. Basic earnings per share from continuing operations was INR 0.27 compared to INR 2.54 a year ago. Diluted earnings per share from continuing operations was INR 0.27 compared to INR 2.54 a year ago.
For the nine months, sales was INR 2,761.56 million compared to INR 3,128.17 million a year ago. Revenue was INR 2,812.89 million compared to INR 3,302.02 million a year ago. Net income was INR 56.55 million compared to INR 129.66 million a year ago. Basic earnings per share from continuing operations was INR 3.57 compared to INR 8.19 a year ago. Diluted earnings per share from continuing operations was INR 3.57 compared to INR 8.19 a year ago.